BioSpace News Archive

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced that Sheila Oren, M.D., M.B.A., was appointed Chief Executive Officer of Pharma Two B, effective January 1, 2021.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 p.m. EST. The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website

BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine

Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT.

Provides Ortho RTI with worldwide rights to commercialize Buoy Suspension Fractional System in combination with Ortho-R

Ikena Announces Advancement of TEAD Inhibitor IK-930 into IND-Enabling Studies and Unveils a First-in-Class Preclinical Program Targeting KRAS Signaling BOSTON--( BUSINESS WIRE )-- Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The round was led and syndicated b

Investment led by Deerfield Management Company alongside a strategic equity investment from Eli Lilly and Company

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, is pleased to announce the hiring of Dr. Jason M. LePree as Vice President of Scientific Affairs to oversee all technical facets of Elite’s pharmaceutical and product development programs.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET.